霍奇金淋巴瘤中程序性死亡受体 1（PD-1）阻断与异基因造血干细胞移植：时间问题——一项代表法语国家骨髓移植与细胞治疗协会开展的全国性研究 - Suppr

PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

作者信息

Kaphan Eleonore, Bettega Francois, Vallet Nicolas, Fegueux Nathalie, Robin Marie, Bazarbachi Ali, Nguyen Stephanie, Beauvais David, Forcade Edouard, De Oca Maria Carolina Montes, Devillier Raynier, Chevallier Patrice, Loschi Michael, Huynh Anne, Bay Jacques-Olivier, Rubio Marie-Therese, Suarez Felipe, Francois Sylvie, Poire Xavier, Contentin Nathalie, Desmier Deborah, Charbonnier Amandine, Cornillon Jerome, Chantepie Sylvain, Turlure Pascal, Bulabois Claude-Eric, Michonneau David, Villate Alban

机构信息

Hematology and transplantation Unit, Saint Louis Hospital, Assistance Publique des Hopitaux de Paris, Paris.

HP2 Laboratory, INSERM U1042, University Grenoble Alpes, Grenoble.

出版信息

Haematologica. 2024 Oct 1;109(10):3373-3378. doi: 10.3324/haematol.2024.284968.

DOI:10.3324/haematol.2024.284968

PMID:38867585

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11443360/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c900/11443360/84b50c8f4569/1093373.fig1.jpg

相似文献

PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Haematologica. 2024 Oct 1;109(10):3373-3378. doi: 10.3324/haematol.2024.284968.

Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Haematologica. 2012 Apr;97(4):482-90. doi: 10.3324/haematol.2011.049742. Epub 2011 Nov 4.

Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T-Cell lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Am J Hematol. 2021 Jul 1;96(7):834-845. doi: 10.1002/ajh.26200. Epub 2021 May 3.

Risk factors for a severe form of COVID-19 after allogeneic haematopoietic stem cell transplantation: a Société Francophone de Greffe de Moelle et de Thérapie cellulaire (SFGM-TC) multicentre cohort study.

Br J Haematol. 2021 Mar;192(5):e121-e124. doi: 10.1111/bjh.17260. Epub 2021 Feb 1.

Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Exp Hematol. 2008 May;36(5):535-44. doi: 10.1016/j.exphem.2008.01.017. Epub 2008 Mar 17.

Impact of KIR/HLA genetic combinations on double umbilical cord blood transplantation outcomes. Results of a French multicentric retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and the Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI).

Bone Marrow Transplant. 2016 Nov;51(11):1499-1503. doi: 10.1038/bmt.2016.151. Epub 2016 Jun 6.

Treatment of adult ALL with central nervous system involvement at diagnosis using autologous and allogeneic transplantation: a study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Bone Marrow Transplant. 2013 May;48(5):684-90. doi: 10.1038/bmt.2012.213. Epub 2012 Nov 19.

Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study From the Société Francophone de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).

Am J Hematol. 2025 Jul;100(7):1173-1184. doi: 10.1002/ajh.27701. Epub 2025 May 6.

Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Ann Oncol. 2017 Sep 1;28(9):2191-2198. doi: 10.1093/annonc/mdx274.

Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Haematologica. 2010 Jun;95(6):950-5. doi: 10.3324/haematol.2009.017814. Epub 2010 Jan 15.

引用本文的文献

Allogeneic stem cell transplantation with prior pembrolizumab and bendamustine therapy induce complete metabolic response in relapsed/refractory classical hodgkin lymphoma with relapse after nivolumab.

Ann Hematol. 2025 Aug 30. doi: 10.1007/s00277-025-06568-8.

本文引用的文献

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.

Leukemia. 2021 Sep;35(9):2672-2683. doi: 10.1038/s41375-021-01193-6. Epub 2021 Mar 3.

Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain.

Biol Blood Marrow Transplant. 2020 Aug;26(8):1534-1542. doi: 10.1016/j.bbmt.2020.02.003. Epub 2020 Feb 14.

Allogeneic hematopoietic stem cell transplantation in r/r Hodgkin lymphoma after treatment with checkpoint inhibitors: Feasibility and safety.

Eur J Haematol. 2019 Feb;102(2):150-156. doi: 10.1111/ejh.13186. Epub 2018 Nov 28.

Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.

Biol Blood Marrow Transplant. 2019 Jan;25(1):94-99. doi: 10.1016/j.bbmt.2018.08.028. Epub 2018 Sep 6.

Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil.

Blood. 2018 Jul 5;132(1):9-16. doi: 10.1182/blood-2018-02-811174. Epub 2018 May 2.

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

J Clin Oncol. 2018 May 10;36(14):1428-1439. doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27.

Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.

Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1247-53. doi: 10.1080/17425255.2016.1216976. Epub 2016 Aug 16.

The PD-1 Axis Enforces an Anatomical Segregation of CTL Activity that Creates Tumor Niches after Allogeneic Hematopoietic Stem Cell Transplantation.

Immunity. 2016 Jan 19;44(1):143-154. doi: 10.1016/j.immuni.2015.12.008. Epub 2016 Jan 12.

Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.

Blood. 2015 Feb 19;125(8):1333-8. doi: 10.1182/blood-2014-10-609032. Epub 2015 Jan 15.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1. doi: 10.1016/j.bbmt.2014.12.001. Epub 2014 Dec 18.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献